ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
LC-MS/MS-based metabolomics analysis and experimental verification reveal the mechanism of Dahuang Mudan Decoction inhibition with the proliferation of colorectal cancer cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to combine in vitro experiments with cell metabonomics used to explore the anti-colorectal cancer effect of Dahuang Mudan Decoction drug-containing serum.
methodsCCK-8, colony formation assay, and wound healing were utilized to evaluate the effects of DHMDD drug-containing serum on the proliferation and migration of human colorectal cancer cells. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting (WB) were used to measure the factors related to the PI3K/AKT signaling pathway. Furthermore, the potential metabolic mechanism of DHMDD was examined using cell metabolomics analysis.
resultsCCK8 results show that the IC50 of the drug-containing serum for HCT116 cells is 7.8%. Conducting cloning and scratch assays at this concentration, the results show that the drug-containing serum significantly curtailed the proliferation and migration of cells. WB and qRT-PCR showed that the drug-containing serum could significantly reduce the expression levels of AKT1, PI3K, PIK3R1, and PIK3CA and p-PI3K and p-AKT. The results of cellular metabolomics analysis indicate that the drug-containing serum can regulate linoleic acid metabolism, arachidonic acid metabolism, phenylalanine metabolism, and glycerophosphate metabolism of colorectal cancer cells by affecting 18 endogenous metabolites, thus affecting the occurrence and development of cancer cells.
conclusionIn summary, these findings indicate that drug-containing serum of Dahuang Mudan Decoction exhibits effective anti-colorectal cancer activity, promoting cell apoptosis mediated by the PI3K/AKT signaling pathway and participating in the regulation of pathways such as linoleic acid and lipid metabolism. The results underscore the value of Dahuang Mudan Decoction as an important adjunctive therapy for colorectal cancer, proposing new strategies for its treatment.
Indexed as
Identifiers
41706148What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.